Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,852
  • Shares Outstanding, K 70,931
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,060 K
  • EBIT $ -145 M
  • EBITDA $ -147 M
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.68

Options Overview Details

View History
  • Implied Volatility 137.96% (-47.62%)
  • Historical Volatility 221.59%
  • IV Percentile 11%
  • IV Rank 6.17%
  • IV High 664.07% on 10/14/25
  • IV Low 103.37% on 01/16/26
  • Expected Move (DTE 24) 1.14 (28.26%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 349
  • Volume Avg (30-Day) 710
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 6,111
  • Open Int (30-Day) 7,131
  • Expected Range 2.89 to 5.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.49
  • Number of Estimates 6
  • High Estimate $-0.35
  • Low Estimate $-0.55
  • Prior Year $-0.67
  • Growth Rate Est. (year over year) +26.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +94.69%
on 03/30/26
6.95 -42.01%
on 04/10/26
+1.41 (+53.82%)
since 03/20/26
3-Month
2.07 +94.69%
on 03/30/26
6.95 -42.01%
on 04/10/26
+1.16 (+40.42%)
since 01/20/26
52-Week
1.13 +256.64%
on 07/01/25
6.95 -42.01%
on 04/10/26
+2.74 (+212.40%)
since 04/17/25

Most Recent Stories

More News
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space?

While Zentalis’ dose selection marks a significant clinical milestone, the underlying data suggests that Aprea’s APR-1051 may offer a superior therapeutic profile by maintaining daily dosing

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin...

ZNTL : 4.03 (-13.15%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer

AZN : 200.69 (-2.01%)
ZNTL : 4.03 (-13.15%)
MRK : 117.10 (-1.65%)
APRE : 0.9810 (-1.90%)
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib therapeutic...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer   Demonstration of Cyclin E1 protein overexpression...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...

ZNTL : 4.03 (-13.15%)
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval Initiation of the...

ZNTL : 4.03 (-13.15%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 5.36
2nd Resistance Point 5.05
1st Resistance Point 4.54
Last Price 4.03
1st Support Level 3.73
2nd Support Level 3.42
3rd Support Level 2.91

See More

52-Week High 6.95
Fibonacci 61.8% 4.73
Fibonacci 50% 4.04
Last Price 4.03
Fibonacci 38.2% 3.35
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.